Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $10.00 Consensus Target Price from Brokerages

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five ratings firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $10.00.

A number of equities research analysts have recently issued reports on the company. Piper Sandler boosted their price objective on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an "overweight" rating in a report on Monday, November 11th. StockNews.com downgraded Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Thursday, December 19th.

Insider Buying and Selling

In other news, SVP Jason B. Daly sold 43,657 shares of the company's stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $8.61, for a total transaction of $375,886.77. Following the completion of the sale, the senior vice president now owns 13,665 shares of the company's stock, valued at approximately $117,655.65. This represents a 76.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Gautam Patel sold 17,410 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $8.01, for a total transaction of $139,454.10. Following the sale, the director now owns 2,031,476 shares in the company, valued at $16,272,122.76. This represents a 0.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 203,657 shares of company stock valued at $1,667,887 over the last 90 days. 26.56% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Gladius Capital Management LP bought a new position in shares of Amneal Pharmaceuticals in the 3rd quarter valued at $37,000. Quest Partners LLC bought a new position in Amneal Pharmaceuticals in the third quarter valued at about $84,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Amneal Pharmaceuticals during the fourth quarter worth about $81,000. Janney Montgomery Scott LLC bought a new position in shares of Amneal Pharmaceuticals in the fourth quarter worth about $121,000. Finally, Quadrature Capital Ltd acquired a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter valued at approximately $169,000. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock traded down $0.01 during midday trading on Monday, hitting $7.97. 1,382,295 shares of the company were exchanged, compared to its average volume of 1,222,845. Amneal Pharmaceuticals has a 52 week low of $5.01 and a 52 week high of $9.48. The firm has a market capitalization of $2.47 billion, a P/E ratio of -11.72 and a beta of 1.10. The firm's 50 day moving average price is $8.15 and its two-hundred day moving average price is $8.23.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.